Zevra Therapeutics, Inc. (ZVRA) Misses Q4 EPS by 27c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q4 EPS of ($0.67), $0.27 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $12 million versus the consensus estimate of $8.52 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Lifetime Brands closes $60M term loan and extends $200M credit facility